967 related articles for article (PubMed ID: 23109356)
1. Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
Deiana S
Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356
[TBL] [Abstract][Full Text] [Related]
2. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia.
Arnold JC; Boucher AA; Karl T
Curr Pharm Des; 2012; 18(32):5113-30. PubMed ID: 22716133
[TBL] [Abstract][Full Text] [Related]
3. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
[TBL] [Abstract][Full Text] [Related]
6. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
Roser P; Vollenweider FX; Kawohl W
World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):208-19. PubMed ID: 20218784
[TBL] [Abstract][Full Text] [Related]
7. Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity.
Juckel G; Roser P; Nadulski T; Stadelmann AM; Gallinat J
Schizophr Res; 2007 Dec; 97(1-3):109-17. PubMed ID: 17884351
[TBL] [Abstract][Full Text] [Related]
8. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
van Amsterdam J; Brunt T; van den Brink W
J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
[TBL] [Abstract][Full Text] [Related]
9. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
10. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.
Dos Santos RG; Hallak JEC; Crippa JAS
Adv Exp Med Biol; 2021; 1264():29-45. PubMed ID: 33332002
[TBL] [Abstract][Full Text] [Related]
11. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.
Morgan CJ; Gardener C; Schafer G; Swan S; Demarchi C; Freeman TP; Warrington P; Rupasinghe I; Ramoutar A; Tan N; Wingham G; Lewis S; Curran HV
Psychol Med; 2012 Feb; 42(2):391-400. PubMed ID: 21798112
[TBL] [Abstract][Full Text] [Related]
12. What is the mechanism whereby cannabis use increases risk of psychosis?
Luzi S; Morrison PD; Powell J; di Forti M; Murray RM
Neurotox Res; 2008 Oct; 14(2-3):105-12. PubMed ID: 19073418
[TBL] [Abstract][Full Text] [Related]
13. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis.
Morgan CJ; Curran HV
Br J Psychiatry; 2008 Apr; 192(4):306-7. PubMed ID: 18378995
[TBL] [Abstract][Full Text] [Related]
14. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.
Hahn B
Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of Medical Cannabis.
Amin MR; Ali DW
Adv Exp Med Biol; 2019; 1162():151-165. PubMed ID: 31332738
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of the antipsychotic properties of cannabidiol in humans.
Iseger TA; Bossong MG
Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
18. Current Cannabidiol Safety: A Review.
Singh C; Rao K; Yadav N; Vashist Y; Chugh P; Bansal N; Minocha N
Curr Drug Saf; 2023; 18(4):465-473. PubMed ID: 36056846
[TBL] [Abstract][Full Text] [Related]
19. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function.
Morgan CJA; Freeman TP; Hindocha C; Schafer G; Gardner C; Curran HV
Transl Psychiatry; 2018 Sep; 8(1):181. PubMed ID: 30185793
[TBL] [Abstract][Full Text] [Related]
20. High potency cannabis: a risk factor for dependence, poor psychosocial outcomes, and psychosis.
Hall W; Degenhardt L
BMJ; 2015 Mar; 350():h1205. PubMed ID: 25739398
[No Abstract] [Full Text] [Related]
[Next] [New Search]
